News

The latest news and views from bridge therapeutics

07/19/18 Opioid addiction is keeping a high percentage of people out of the workforce, Fed chairman says

America’s opioid epidemic is exacting a massive human toll that also is impacting the economy, Federal Reserve Chairman Jerome Powell said Tuesday. “From an economic standpoint, some high percentage of prime-age people who are not in the labor force, particularly prime-age males who are not in the labor force, are taking painkillers of some kind,” he said.

July 17, 2018

Powell cited research from Princeton economist Alan Krueger, who conducted a survey and found that 44 percent of men reported that they had taken some form of pain medication the previous day.

Read the full article here

07/19/18 Bridge Therapeutics, to Participate in American Chronic Pain Association Roundtable With Agenda for Chronic Pain Drug Development Program

Executives with the innovative late development-stage pharmaceutical startup, Bridge Therapeutics, announced they will be introducing their chronic pain development program at the American Chronic Pain Association (ACPA) Roundtable. The ACPA offers peer support and education in pain management skills to people with chronic pain, along with their families, friends, and healthcare professionals.

July 11, 2018

Alton Kelley, Director of Business Development for Bridge Therapeutics, said this roundtable will give the chronic pain community an opportunity to learn more about Bridge Therapeutics’ current developments on pain relievers and promoting the ACPA’s efforts in fighting chronic pain.

Read the full article here

07/10/18 Pharma Startup, Bridge Therapeutics, Will Unveil Its Chronic Pain Drug Development Program at the 2018 Young Startup Ventures Summit in New York

Executives with the innovative late development-stage pharmaceutical startup, Bridge Therapeutics, announced they would showcase their chronic pain drug development program to venture capitalists at the 2018 Young Startup Ventures Summit in New York.

July 9, 2018

More than 150 venture capitalists will hear pitches and programs from various companies and startups in fields ranging from fintech to life sciences. The 2018 New York Venture Summit will take place at Convene in New York on July 10-11. Tim Peara said this forum would enable venture capitalist to hear how Bridge’s work towards developing a safer alternative for chronic pain has been progressing.

Read More

06/27/18 The NIH Announces New Research Initiative to Fight Opioid Addiction

The National Institutes of Health (NIH) recently announced a new set of research priorities around addiction and pain research in efforts to combat the nation’s opioid crisis.

June 22nd, 2018

The HEAL (Helping to End Addiction Long-term) Initiative was launched by the NIH with support from the president and the Department of Health and Human Services. Under this ambitious new research program, the NIH will invest resources to aid the discovery of scientific solutions for opioid addiction and pain management.

Read the full article here

06/13/18 BIO2018 Makes History in Boston

Bridge Builds Connections at World’s Largest Business Partnering Event.

June 7, 2018

The Bridge Therapeutics Team traveled to Boston for the BIO International Convention. Bridge met with investors as well as worked to attain other sources of capital. The team, also, met with vendors and service providers in preparation for the launch of their lead investigational drug BT-205. Bridge’s Tim Peara, Alton Kelley, and Dave Bergstrom were a part of the nearly 47,000 partnering meetings that occurred making them a part of the Guinness Book of World Records “Largest Business Partnering Event”.

“We’re really hoping to work with investors on financing so we can get our drug to the FDA,” said Alton Kelley, the firm’s director of business development. “We’re going to need a little more capital to get it through the finish line.”

Read the full article here

05/29/18 Opioid Receptor Agonist Market Pipeline Therapeutics 2018 Top Key Players

Opioid Receptor Agonist Market Pipeline Review provides comprehensive information on the therapeutics under development and growth prospect for Opioid Receptor Agonist Market.

May 29, 2018

Bridge Therapeutics was named one of the key players of the opioid receptor agonist market of therapeutics in developmental phase by Journal Healthcare. Buprenorphine, a partial agonist of the Mu opioid receptor (MOR) gives it advantages over traditional, full agonist opioids in that it is less addictive and safer. The therapeutic market for Mu agonist opioids are typically related to pain relief and opioid addiction.

Journal Healthcare offers news and resources to the public and features news and resources focused on all areas of healthcare including diseases, medicines, fitness, among others.

Read the full article Here

05/16/18 Pharmaceutical Startup, Bridge Therapeutics, Announces New Headquarters in Birmingham, Alabama

Bridge Therapeutics has announced they will be expanding their operations into one of the finest locations in Birmingham, Alabama. The new headquarters at the Summit in Birmingham is currently under design by the award-winning architectural firm Chambless King Architects.

May 16, 2018

“Our new headquarters will bring a new energy to Bridge Therapeutics,” said Alton Kelley, Director of Business Development. “We are all excited about this next step. We hope our new headquarters will attract other businesses to the Birmingham area, and ignite new economic growth in our community.”

John Chambless, the lead architect behind the new office design, said he wanted the new space to convey a sense of growth and change to investors and partners who visit there.

Read the full article here

 

04/16/18 Medicare Announces New Guidelines on High-Dose Opioids

Aiming for an “overall reduction in opioid overuse and overdoses,” Medicare announces starting next year there will be new limits for high-dose opioid prescriptions.

APRIL 12, 2018

The Medicare announcement—part of the 2019 Medicare Advantage and Part D Rate Announcement and Call Letter— sets limits for opioid-naive patients on seven-day prescriptions, and notes the expansion and combination of the Overutilization Monitoring System and other government facets to identify “high-risk” opioid users, defined as using high levels of opioids from multiple sources, and “potentiator” users, who are using other medications (e.g., benzodiazepines) that increase the risk for adverse effects from opioids.

Journal Healthcare offers news and resources to the public and features news and resources focused on all areas of healthcare including diseases, medicines, fitness, among others.

Read the full article here

03/14/18 Pharmaceutical Startup, Bridge Therapeutics, Announces Tim Peara Will Be Joining the Company as the Director of Finance

The innovative late development-stage pharmaceutical startup, Bridge Therapeutics has announced Tim Peara will be joining its management team as the new Director of Finance, effective immediately.

March 14, 2018

Tim Peara has more than 30 years of experience with institutional investments and technology start-ups. He has negotiated and structured investments, conducted due diligence, and built financial models for companies in finance, energy tech, and industry. Mr. Peara has also built and led teams while consulting to a variety of businesses.

Tim holds a BA in Latin American Studies from Wesleyan University in Connecticut and an MBA in Finance & International Business from the University of Chicago’s Booth School of Business.

Read More

02/27/18 Is Abuse of a Nerve Pain Drug On the Rise? FDA Intends to Find Out

Greg Sullivan, MD, Chief Scientific Officer and CEO of Bridge Therapeutics, was recently interviewed by Bronwyn Mixter of Bloomberg BNA about the abuse of gabapentinoid pain drugs. Dr. Sullivan explains how buprenorphine is a safe alternative for many of the dangerous drugs that are currently prescribed for chronic pain.

February 27, 2018

In the article Dr. Sullivan discusses the advantages of Buprenorphine compared to other opioids “buprenorphine was originally developed as a pain drug in the 1970s. Patients who take the drug don’t have euphoria, and it has no sedation and overdose risks” he said. He also went on to recommend “If patients need to stay on a pain drug for more than the standard two weeks when pain becomes chronic, they could switch to buprenorphine and get pain relief without the problems of tolerance, dependence, and lack of pain control” Sullivan said.

Bloomberg BNA is an affiliate of Bloomberg L.P., the global business, financial information and news leader.

Read the full article here

For more information about Bridge Therapeutics please contact us today using the form below.